Advances in treating premature ejaculation

Selahittin Çayan¹ and Ege Can Şerefoğlu²

Addresses: ¹Department of Urology, University of Mersin School of Medicine, Çiftlikköy Kampusu 33343 Yenisehir, Mersin, Turkey; ²Department of Urology, Başcilar Training and Research Center, Merkez Mah No:6 34200 Başcilar, İstanbul, Turkey

* Corresponding author: Selahittin Çayan (selcayan@mersin.edu.tr)

F1000Prime Reports 2014, 6:55 (doi:10.12703/P6-55)

All F1000Prime Reports articles are distributed under the terms of the Creative Commons Attribution-Non Commercial License (http://creativecommons.org/licenses/by-nc/3.0/legalcode), which permits non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

The electronic version of this article is the complete one and can be found at: http://f1000.com/prime/reports/m/6/55

Abstract

In spite of its high prevalence and long history, the ambiguity regarding the definition, epidemiology and management of premature ejaculation continues. Topical anesthetic creams and daily or on-demand selective serotonin reuptake inhibitor (SSRI) treatment forms the basis of pharmacotherapy for premature ejaculation today, in spite of low adherence by patients. Psychotherapy may improve the outcomes when combined with these treatment modalities. Tramadol and phosphodiesterase type 5 inhibitors have a limited role in the management of premature ejaculation. Further research is required to develop better options for the treatment of this common sexual disorder.

Introduction

Although premature ejaculation was first described over a century ago [1], the ambiguity regarding its definition, epidemiology and management continues [2]. Recently, the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) [3] (published by the American Psychiatric Association) defined premature ejaculation and, contrary to previous versions of this manual, it included the parameter of approximately one minute intravaginal ejaculatory latency time (IELT). The DSM-5 also listed potential exclusionary conditions, to include nonsexual mental disorders, severe relationship distress or other significant stressors and substance/medication use or other medical disorders, which may result in early ejaculations. These criteria were intended to eliminate cases of premature ejaculation resulting secondarily from psychological and/or medical factors. However, the sexual complaints of patients who seek treatment for premature ejaculation are varied, and a significant amount of them do not fulfill the criteria of the definition in DSM-5 [4,5]. Therefore, the concerns of these men must also be addressed by health care providers and available therapeutic options must be offered. The aim of this review is to summarize the contemporary advances in premature ejaculation treatment and provide a broad insight into the efficacy and safety of these options.

Psychotherapy

Historically, premature ejaculation was considered to be a psychological or partner-related condition due either to anxiety or to conditioning towards rapid ejaculation based on rushed early sexual experiences [6,7]. Therefore, psychotherapy was the initial treatment modality proposed for premature ejaculation, although its utility is limited in today’s practice.

Psychotherapy may help men improve their sexual skills and enable them to control their ejaculation. Moreover, broadening the sexual knowledge of a man with premature ejaculation may aid him in increasing his sexual self-confidence and reduce performance anxiety. More importantly, psychotherapy may resolve psychological and interpersonal problems which may be the cause and/or result of premature ejaculation [8,9]. Unfortunately, the majority of the psychotherapy studies dealing with premature ejaculation do not meet the criteria for high level evidence-based studies [8], so it is now recommended that psychotherapy be used in conjunction with pharmacotherapy [10].
The initially developed and most frequently used behavioral treatments include the “squeeze” technique, which was later modified to become the “stop–start” method [6,11]. Both of these techniques were suggested to assist men in identifying their excitement levels by a series of graduated exercises. These exercises begin with self-stimulation, moving on to partner hand stimulation, then to intercourse without movement, and finally to stop/start thrusting. This treatment modality is hypothesized to result in an increase in IELT, but there are no reliable data to support this claim [6,12-14]. Two recently published meta-analyses concluded that there is weak and inconsistent evidence regarding the effectiveness of psychological interventions for the treatment of premature ejaculation, confirming the need for future research in this field [15,16].

Topical anesthetics
Hypersensitivity of the glans penis is another one of the proposed etiological factors underlying the pathophysiology of premature ejaculation [17]. Therefore, the use of topical anesthetics to diminish the sensitivity of the glans penis was one of the first pharmacological treatment alternatives for premature ejaculation [7].

Lidocaine-prilocaine cream is the most studied local anesthetic for treating premature ejaculation. A randomized, double-blind, placebo-controlled trial demonstrated that 5% lidocaine-prilocaine cream significantly increased the IELT when applied for 20 minutes prior to sexual intercourse [18]. Another controlled study showed that a combination of sildenafil and lidocaine-prilocaine cream is superior to placebo, and either as monotherapy, in the treatment of premature ejaculation [19]. A recently developed lidocaine/prilocaine-containing spray (topicaleutectic mixture for premature ejaculation; TEMPE Plethora Solutions Ltd, London, UK) has been shown to increase IELT 6.3-fold and improved patient-reported outcome measures of control and sexual satisfaction [20]. Another topical anesthetic agent developed for premature ejaculation is SS-cream, which is made from the extracts of nine herbs [21]. A well-controlled study showed that SS-cream increased IELT from 1.37 to 10.92 minutes and 82% of patients reported improved sexual satisfaction [22]. Frequently reported side effects include penile hypoesthesia and transfer to the partner, resulting in vaginal numbness and resultant female anorgasmia unless a condom is used [23].

Selective serotonin reuptake inhibitors
Disregulation in central serotonergic neurotransmission is hypothesized as one of the etiologic factors underlying premature ejaculation [24,25]. Serotonin is the most important neurotransmitter in the control of ejaculation and its impact on ejaculation has been demonstrated in animal and human models [26-28]. The introduction of tricyclic antidepressants and SSRIs for the treatment of premature ejaculation has revolutionized our understanding of this problem and completely altered its management. These drugs block the axonal re-uptake of serotonin from the synaptic cleft and increase 5-HT neurotransmission through enhanced stimulation of post-synaptic membrane 5-HT receptors. Today, most premature ejaculation patients are treated either with on-demand SSRIs (dapoxetine) or with daily dosing of paroxetine, clomipramine, sertraline, fluoxetine or citalopram [25,29-38] (Table 1).

Daily treatment with paroxetine 10-40 mg, clomipramine 12.5-50 mg, sertraline 50-200 mg, fluoxetine 20-40 mg, and citalopram 20-40 mg is usually effective in delaying ejaculation [29-31,34,37,39]. Among these agents, paroxetine seems to exert the most pronounced delay in ejaculation, increasing IELT approximately 8.8-fold over baseline [40]. Improvement in IELT may occur within 5-10 days of starting treatment, but a minimum of 2-3 weeks is necessary to observe the maximal therapeutic effect [41]. Reported side effects are usually minor, may start within the first week of treatment and may gradually disappear within 2-3 weeks [42]. These side effects include fatigue, yawning, mild nausea, diarrhea, insomnia, and constipation [42]. Hypoactive desire and erectile dysfunction are also reported [43]. Of note, SSRIs must be used with caution in premature ejaculation patients who desire fertility, as these drugs are associated with impaired sperm parameters [44-46].

Premature ejaculation patients may not adhere to SSRI treatment. Salonia et al. [47] reported that 30% of patients refused to begin treatment (paroxetine, 10 mg daily for 21 days followed by 20 mg as needed) and another 30% of those that began treatment discontinued it. Reasons given for discontinuing treatment included not wanting to take an antidepressant, treatment effects below expectations, temporary loss of interest in sex because of relationship issues and side effects [47].

Dapoxetine is a rapid acting SSRI with a short half-life that was the first approved oral medication for the treatment of premature ejaculation. Its pharmacokinetic profile enables its on-demand use [32,33,35,48,49]. In several well-controlled studies, dapoxetine 30 mg or 60 mg (taken 1-2 hours before intercourse) is shown to increase IELT 2.5- and 3.0-fold and improve the patient-reported outcome measures [35,50,51]. Treatment related side effects were uncommon, dose dependent and included nausea, diarrhea, headache, and dizziness [35,49]. It should be remembered that many men with premature ejaculation may prefer the convenience
Table 1: Medical treatment options for premature ejaculation [58]

| Therapy type   | Drug                      | Trade name              | Dose                        | IELT fold increase |
|----------------|---------------------------|-------------------------|-----------------------------|--------------------|
| Topical therapy | Lidocaine/prilocaine cream [29] | EMLA® cream             | 25 mg/gm lidocaine, 25 mg/gm prilocaine | 4-6               |
| Oral therapy   | Dapoxetine [35,49,31,39]   | Priligy®                | 30-60 mg on demand          | 2.5-3             |
| Oral therapy   | Clomipramine [30,34,38]    | Anafrani®               | 12.5-50 mg/day or           | 6                 |
|                |                           |                         | 12.5-50 mg on demand        | 4                 |
| Oral therapy   | Fluoxetine [56,64,23,66-68] | Prozac®, Sarafem®       | 20-40 mg/day                | 5                 |
| Oral therapy   | Paroxetine [36-38,60]      | Paxil®, Seroxat®        | 10-40 mg/day or             | 8                 |
| Oral therapy   | Sertraline [59,64,61-66]   | Zoloft®                 | 10-40 mg/day on demand      | 1.4               |
| Oral therapy   | Citalopram [67-68]        | Celexa®, Cipramil®      | 62 mg ODT on demand or 89 mg ODT on demand | 2.4               |
| Oral therapy   | Tramadol [69]             | Zertane®                |                             | 2.5               |

of daily treatment which does not interfere with the spontaneity of having sex [52]. Similar to daily SSRI treatment, 20% of premature ejaculation patients do not start on-demand dapoxetine, mostly because of the fear of using a “drug” and the cost of the treatment [53]. Of the patients who initiated dapoxetine treatment, 90% discontinued this treatment within 1 year. The main reasons were effect below expectations (24.4%), costs (22.1%), side effects (19.8%), loss of interest in sex (19.8%), and no efficacy (13.9%) [53].

Using antidepressants is not without risks. Although risk of suicidal ideation among young adolescents with depressive and/or anxiety disorders slightly increases with SSRI treatment [54], such a risk was not detected in SSRI studies on adult men with premature ejaculation [35,36,38]. However, physicians must be aware of this risk while prescribing antidepressants to patients with premature ejaculation.

**Tramadol**

Tramadol is a centrally acting opioid analgesic and several studies have demonstrated that it may increase IELT when administered daily or on-demand [57]. Several well-controlled clinical studies confirmed that 25-100 mg tramadol treatment results in a 2.4-12.6-fold increase in IELT from baseline [58-60,64]. Although tramadol may be considered an effective option for the treatment of premature ejaculation, the risk of addiction and its side effects limit its wide-spread use. Somnolence, pruritus, dizziness, dryness of mouth, nausea and vomiting are frequently seen undesirable effects with the use of tramadol, the severity of which were dose-dependent [60]. More importantly, combining tramadol with an SSRI may result in potentially fatal serotonin syndrome, thus this medication should only be used with caution in selected patients [61].

**Phosphodiesterase type 5 inhibitors**

Although the efficacy of phosphodiesterase type 5 inhibitors in treating premature ejaculation has been studied by several authors [62-65], they also have a limited role in the management of premature ejaculation in men who have co-morbid erectile dysfunction [66-67]. Men who have conditioned themselves to ejaculate rapidly because of a softening erection may experience improvements in their premature ejaculation under phosphodiesterase type 5 inhibitor treatment.

**Other drugs and treatments**

Dopamine and oxytocin appear to have a stimulatory effect on ejaculation [68-69]. When administered into the cerebral ventricles of male rats, oxytocin has been demonstrated to shorten ejaculation latency and post-ejaculatory refractory period [70]. Similarly, systemic oxytocin administration has been demonstrated to shorten ejaculation latency and post-ejaculatory interval in sexually active male rats [71]. In an attempt to understand the potential role for anti-oxytocin drugs in the treatment of premature ejaculation, several studies have demonstrated that central administration of selective oxytocin-receptor antagonists inhibit sexual behavior, including ejaculation, in male rats [72,73]. A recent study demonstrated that a highly selective, non-peptide oxytocin antagonist may inhibit ejaculation when administered both peripherally and centrally [68], which may be a promising alternative for the treatment of premature ejaculation. However, future well-designed human trials are necessary to confirm that oxytocin receptors are future targets for pharmacotherapy of premature ejaculation.

Various treatment alternatives have been introduced for treating premature ejaculation. In a randomized placebo-controlled trial, acupuncture therapy has been demonstrated to be effective in delaying ejaculation, compared to placebo [74]. However, the authors also noted that acupuncture was less effective than daily paroxetine treatment.

Several other authors investigated the impact of ablation and modulation of the dorsal penile nerve [75,76]. Prologo et al. [75] demonstrated that unilateral CT-guided
percutaneous cryoablation of the dorsal penile nerve resulted in a significant increase in IELT and improved patient-reported outcome measures as well. Recently, Basal et al. [76] assessed the role of percutaneous pulsed radiofrequency ablation of bilateral dorsal penile nerves in the treatment of premature ejaculation. Similarly, they noted mean IELT was significantly increased among men with lifelong premature ejaculation. In spite of these promising results, the invasive and irreversible nature of these procedures must be considered before recommending these modalities to premature ejaculation patients, and further clinical trials are required to assess their safety and long term efficacy.

**Conclusion**

Topical anesthetic creams and daily or on-demand SSRI treatment form the basis of pharmacotherapy for premature ejaculation today, in spite of low adherence by patients. Psychotherapy may improve the outcomes when it is combined with these treatment modalities. Tramadol and phosphodiesterase type 5 inhibitors have limited roles in the management of premature ejaculation. Further research is required to develop better options for the treatment of this disorder.

**Abbreviations**

DSM-5, Diagnostic and Statistical Manual of Mental Disorders, fifth edition; IELT, intravaginal ejaculatory latency time; SSRI, selective serotonin reuptake inhibitor.

**Disclosures**

Ege Can Şerefoglu is serving as a consultant for Allergan Company.

**References**

1. Gross S: Practical treatise on impotence and sterility and allied disorders of the male sexual organs. Edinburg: YJ Pentland; 1887.
2. Şerefoglu EC, Saitz TR: New insights on premature ejaculation: a review of definition, classification, prevalence and treatment. Asian J Androl 2012, 14:822-9.
3. American Psychiatric Association: The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition. Washington, DC: American Psychiatric Association; 2013.
4. Şerefoglu EC, Cimen HI, Atmaca AF, Balbay MD: The distribution of patients who seek treatment for the complaint of ejaculating prematurely according to the four premature ejaculation syndromes. J Sex Med 2010, 7:810-5.
5. Zhang X, Gao J, Liu J, Xia L, Yang J, Hao Z, Zhou J, Liang C: Distribution and Factors Associated with Four Premature Ejaculation Syndromes in Outpatients Complaining of Ejaculating Prematurely. J Sex Med 2013, 10:1603-11.
6. Masters W, Johnson V: Human Sexual Inadequacy. Boston: Little, Brown; 1970.
7. Schapiro B: Premature ejaculation, a review of 1130 cases. J Urol 1943, 50:374-79.
8. Althof S: Psychological approaches to the treatment of rapid ejaculation. J Mens Health Gend 2006, 3:180-86.
9. Althof S: Treatment of Rapid Ejaculation: Psychotherapy, Pharmacotherapy, and Combined Therapy. In Leiblum S ed. Principles and Practice of Sex Therapy. (4th Edition) New York: Guilford Press; 2007, 212-40.
10. Rowland D, Cooper S: Practical tips for sexual counseling and psychotherapy in premature ejaculation. J Sex Med 2011, 8 (Suppl 4):342-52.
11. Semans J: Premature ejaculation. South Med J 1956, 49:352-58.
12. Hawton K: Treatment of sexual dysfunctions by sex therapy and other approaches. Br J Psychiatry 1995, 167:307-14.
13. De Carufel F, Trudel G: Effects of a new functional sexological treatment for premature ejaculation. J Sex Ment Health 2006, 32:97-114.
14. Trudel G, Proulx S: Treatment of premature ejaculation by bibliotherapy: An experimental study. Sex Ment Health 1987, 36:33.
15. Fruhauf S, Garger H, Schmidt H, Munder T, Barth J: Efficacy of Psychological Interventions for Sexual Dysfunction: A Systematic Review and Meta-Analysis. Arch Sex Behav 2013, 42:915-33.
16. Melnik T, Althof S, Ayallah A, Pugs MS, Glina S, Riera R: Psychosocial interventions for premature ejaculation. Cochrane Database Syst Rev 2011, 8:CD008195.
17. Xin ZC, Choi YD, Rha KH, Choi HK: Somatosensory evoked potentials in patients with primary premature ejaculation. J Urol 1997, 158:451-5.
18. Atikeler MK, Gecl T, Senol FA: Optimum usage of prilocaine-lidocaine cream in premature ejaculation. Andrologia 2002, 34:356-9.
19. Atan A, Basar MM, Tuncel A, Ferhat M, Agras K, Tekdogan U: Comparison of efficacy of sildenafil-only, sildenafil plus topical EMLA cream, and topical EMLA-cream-only in treatment of premature ejaculation. Urol 2006, 67:388-91.
20. Dinsmore WW, Hackett G, Goldmeier D, Waldinger M, Dean J, Wright P, Callender M, Wyllie MG, Wright P, Callander M, Wyllie MG: Topical eutectic mixture for premature ejaculation (TEMPE): a novel aerosol-delivery form of lidocaine-prilocaine for treating premature ejaculation. BJU Int 2007, 99:369-75.
21. Morales A, Barada J, Wyllie MG: A review of the current status of topical treatments for premature ejaculation. BJU Int 2007, 100:163-7.
22. Choi HK, Jung GW, Moon KH, Xin ZC, Choi YD, Lee VH, Rha KH, Choi YJ, Kim DK: Clinical study of SS-cream in patients with lifelong premature ejaculation. Urol 2000, 55:257-61.
23. Busato W, Galindo CC: Topical anesthetic use for treating premature ejaculation: a double-blind, randomized, placebo-controlled study. Br J Urol Int 2004, 93:1018-21.
24. Giuliano F: 5-Hydroxytryptamine in premature ejaculation: opportunities for therapeutic intervention. Trends Neurosci 2007, 30:79-84.
25. Waldinger M, Berendson HH, Blok BF, Olliver B, Holstege G: Premature ejaculation and serotonergic antidepressants-induced delayed
ejaculation: the involvement of the serotonergic system. Behav Brain Res 1998, 92:111-8.
26. Waldinger M: The neurobiological approach to premature ejaculation. J Urol 1998, 168:2339-67.
27. Waldinger M, Schweitzer DH: The use of old and recent DSM definitions of premature ejaculation in observational studies: a contribution to the present debate for a new classification of PE in the DSM-IV. J Sex Med 2008, 5:1079-87.
28. Janssen PK, Bakker SC, Rethelyi J, Zwinderman AH, Touw DJ, Olivier B, Waldinger MD: Serotonin transporter promoter region (5-HTTLPR) polymorphism is associated with the intravaginal ejaculation latency time in Dutch men with lifelong premature ejaculation. J Sex Med 2009, 6:276-84.

29. Althof S, Levine S, Coryt E, Risen C, Stern E, Kurit D: A double-blind crossover trial of clomipramine for rapid ejaculation in 15 couples. J Clin Psychiatry 1995, 56:402-7.
30. Atmaca M, Kuloglu M, Tezcan E, Semercioz A: The efficacy of citalopram in the treatment of premature ejaculation: a placebo-controlled study. Int J Impot Res 2002, 14:502-5.
31. Goodman RE: An assessment of clomipramine (Anafranil) in the treatment of premature ejaculation. Int J Impot Res 1998, 8:53-9.
32. Sangkum P, Badr R, Serefoglu EC, Hellstrom WJ: Dapoxetine for the treatment of men with premature ejaculation (PE):dose-finding analysis. J Urol 2005, 173:218.abstract 877.
33. McMahon C, Kim SW, Park NC, Chang CP, Rivas D, Tesfaye F, Rothman M, Aquilina J: Dapoxetine 3003 Study Investigators: Treatment of Premature Ejaculation in the Asia-Pacific Region: Results From a Phase III Double-blind, Parallel-group Study of Dapoxetine. J Sex Med 2009, 7:256-68.
34. McMahon CG: Treatment of premature ejaculation with sertraline hydrochloride: a single-blind placebo controlled crossover study. J Urol 1998, 159:1935-8.
35. McMahon CG, Althof SE, Kaufman JM, Buvat J, Levine SB, Aquilina JW, Tesfaye F, Rothman M, Rivas DA, Portz H: Efficacy and safety of dapoxetine for the treatment of premature ejaculation: integrated analysis of results from five phase 3 trials. J Sex Med 2011, 8:524-39.
36. McMahon CG, Tuncuma K: Treatment of premature ejaculation with paroxetine hydrochloride as needed: 2 single-blind placebo controlled crossover studies. J Urol 1999, 161:1826-30.
37. Waldinger MD, Hengedal MW, Zwinderman AH: Paroxetine treatment of premature ejaculation: a double-blind, randomized, placebo-controlled study. Am J Psychiatry 1994, 151:1377-9.
38. Waldinger MD, Zwinderman AH, Olivier B: On-demand treatment of premature ejaculation with clomipramine and paroxetine: a randomized, double-blind fixed-dose study with stopwatch assessment. Eur Urol 2004, 46:510-15.
39. Kara H, Aydin S, Yucel M, Argurgun MY, Odabas O, Yilmaz Y: The efficacy of fluoxetine in the treatment of premature ejaculation: a double-blind placebo controlled study. J Urol 1996, 156:1631-2.
40. Waldinger M, Zwinderman A, Schweitzer D, Olivier B: Relevance of methodological design for the interpretation of efficacy of drug treatment of premature ejaculation: A systematic review and metaanalysis. Int J Impot Res 2004, 16:369-81.
41. McMahon CG: Long term results of treatment of premature ejaculation with selective serotonin re-uptake inhibitors. Int J Impot Res 2002, 14:519.
42. Montejo AL, Llorca G, Lizardo JA, Rico-Villademoros F: Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. Spanish Working Group for the Study of Psychotrophic-Related Sexual Dysfunction. J Clin Psychiatry 2001, 62(Suppl 3):10-21.
43. Waldinger MD: Premature ejaculation: definition and drug treatment. Drugs 2007, 67:547-68.
44. Koyuncu H, Serefoglu EC, Ozdemir AT, Hellstrom WJ: Deleterious effects of selective serotonin reuptake inhibitor treatment on semen parameters in patients with lifelong premature ejaculation. Int J Impot Res 2012, 24:171-3.
45. Koyuncu H, Serefoglu EC, Yencilek E, Ayalay H, Akbas NB, Sarica K: Escitalopram treatment for premature ejaculation has a negative effect on semen parameters. Int J Impot Res 2011, 23:257-61.
46. Tanikut C, Feldman AS, Altemus M, Paduch DA, Schlegel P: Adverse effect of paroxetine on sperm. Fertil Steril 2010, 94:1021-6.
47. Salonia A, Rocchini L, Sacca‘ A, Pellucchi F, Ferrari M, Carro UD, Ribotto P, Gallina A, Zanni G, Debo’ F, Rigatti P, Montorsi F: Acceptance of and discontinuation rate from paroxetine treatment in patients with lifelong premature ejaculation. J Sex Med 2009, 6:2868-77.
48. Buvat J, Tesfaye F, Rothman M, Rivas DA, Giuliano F: Dapoxetine for the treatment of premature ejaculation: results from a randomized, double-blind, placebo-controlled phase 3 trial in 22 countries. Eur Urol 2009, 55:957-67.
49. Pryor JL, Althof SE, Steidie C, Rosen RC, Hellstrom WJ, Shabirg R, Miloslavsky M, Kell S: Dapoxetine Study Group: Efficacy and tolerability of dapoxetine in treatment of premature ejaculation: an integrated analysis of two double-blind, randomised controlled trials. Lancet 2006, 368:929-37.
50. Jannini EA: Editorial comment on: Dapoxetine for the treatment of premature ejaculation: results from a randomized, double-blind, placebo-controlled phase 3 trial in 22 countries. Eur Urol 2009, 55:967-8.
51. Porst H, McMahon C, Althof S, Sharlip I, Bull S, Rivas DA: Baseline characteristics and treatment outcomes for men with acquired or lifelong premature ejaculation with mild or no erectile dysfunction: Integrated analysis of two phase III dapoxetine trials. J Sex Med 2010, 7:2231-42.
52. Waldinger MD, Zwinderman AH, Olivier B, Schweitzer DH: The majority of men with lifelong premature ejaculation prefer daily drug treatment: an observation study in a consecutive group of Dutch men. J Sex Med 2007, 4:1028-37.
53. Mondaini N, Fusco F, Cai T, Benemel S, Mirone V, Bartoletti R: Dapoxetine treatment in patients with lifelong premature ejaculation: the reasons of a “Waterloo”. Urol 2013, 82:620-4.
56. Bar-Or D, Salottolo KM, Orlando A, Winkler JV: Tramadol ODTSG: A randomized double-blind, placebo-controlled multicenter study to evaluate the efficacy and safety of two doses of the tramadol orally disintegrating tablet for the treatment of premature ejaculation within less than 2 minutes. *Eur Urol* 2012, 61:736-43.

57. Safarinejad MR, Hosseini SY: Safety and efficacy of tramadol hydrochloride on treatment of premature ejaculation. *Urology* 2012, 79:145-9.

58. Kaynar M, Kilic O, Yurdakul T: On-demand tramadol hydrochloride use in premature ejaculation treatment. *Urology* 2012, 79:145-9.

59. Salem EA, Wilson SK, Bissada NK, Delk JR, Hellstrom WJ, Cleves MA: Tramadol HCL has promise in on-demand use to treat premature ejaculation. *J Sex Med* 2008, 5:188-93.

60. Eassa BI, El-Shazly MA: Safety and efficacy of tramadol hydrochloride on treatment of premature ejaculation. *Asian J Androl* 2013, 15:138-42.

61. Takeshita J, Litzinger M: Serotonin syndrome associated with tramadol. *Prim Care Companion J Clin Psychiatry* 2009, 11:273.

62. Aversa A, Pili M, Francomano D, Bruzziches R, Sperta E, La Pera G, Sperta G: Effects of vardenafil administration on intravaginal ejaculatory latency time in men with lifelong premature ejaculation. *Int J Impot Res* 2009, 21:221-7.

63. Jannini EA, McMahon C, Chen J, Aversa A, Perelman M: The controversial role of phosphodiesterase type 5 inhibitors in the treatment of premature ejaculation. *J Sex Med* 2011, 8:2135-43.

64. McMahon CG, Stuckey B, Andersen ML: Efficacy of Viagra: Sildenafil Citrate in Men With Premature Ejaculation. *J Sex Med* 2005, 2:368-75.

65. Salonia A1, Maga T, Colombo R, Scattoni V, Briganti A, Castani A, Guazzoni G, Rigatti P, Montorci F: A prospective study comparing paroxetine alone versus paroxetine plus sildenafil in patients with premature ejaculation. *J Urol* 2002, 168:2486-9.

66. Asumakopoulos AD, Miano R, Finazzi Agro E, Vespasiani G, Sperta E: Does current scientific and clinical evidence support the use of phosphodiesterase type 5 inhibitors for the treatment of premature ejaculation? a systematic review and meta-analysis. *J Sex Med* 2012, 9:2404-16.

67. McMahon CG, McMahon CN, Leow LJ, Winestock CG: Efficacy of type-5 phosphodiesterase inhibitors in the drug treatment of premature ejaculation: a systematic review. *Br J Urol Int* 2006, 98:259-72.

68. Clement P, Bernabe J, Compagnie S, Alexandre L, McCallum S, Giuliano F: Inhibition of ejaculation by the non-peptide oxytocin receptor antagonist GSK557296: a multi-level site of action. *Br J Pharmacol* 2013, 169:1477-85.

69. Clement P, Pozzato C, Heidbreder C, Alexandre L, Giuliano F, Melotto S: Delay of ejaculation induced by SB-277011, a selective dopamine D3 receptor antagonist, in the rat. *J Sex Med* 2009, 6:980-8.

70. Arletti R, Bazzani C, Castelli M, Bertolini A: Oxytocin improves male copulatory performance in rats. *Horm Behav* 1985, 19:1-4-20.

71. Stoneham MD, Everitt BJ, Hansen S, Lightman SL, Todd K: Oxytocin and sexual behaviour in the male rat and rabbit. *J Endocrinol* 1985, 107:97-106.

72. Artigol A, Collu M, D’Aquila P, Gessa GL, Melis MR, Serra G: Apomorphine stimulation of male copulatory behavior is prevented by the oxytocin antagonist d(CH2)5 Tyr(Me)-Orn8-vasotocin in rats. *Pharmacol Biochem Behav* 1989, 33:81-3.

73. Clement P, Peeters M, Bernabe J, Depuis P, Alexandre L, Giuliano F: Brain oxytocin receptors mediate ejaculation elicited by 7-hydroxy-2-(di-N-propylamino) tetralin (7-OH-DPAT) in anaesthetized rats. *Br J Pharmacol* 2008, 154:1150-9.

74. Sunay D, Sunay M, Aydoğan Y, Başbanci S, Arslan H, Karabulut A, Emir L: Acupuncture versus paroxetine for the treatment of premature ejaculation: a randomized, placebo-controlled clinical trial. *Eur Urol* 2011, 59:765-71.

75. David Prologo J, Snyder LL, Cherullo E, Passalacqua M, Pirasteh A, Corno D: Percutaneous CT-guided cryoablation of the dorsal penile nerve for treatment of symptomatic premature ejaculation. *J Vasc Interv Radiol* 2013, 24:214-9.

76. Basal S, Goktas S, Ergin A, Yıldırım I, Acun A, Tahanz L, Dayanc M: A novel treatment modality in patients with premature ejaculation resistant to conventional methods: the neuro modulation of dorsal penile nerves by pulsed radiofrequency. *J Androl* 2010, 31:126-30.